Hoechst And Roussel Merger In The UK

2 October 1994

As of the beginning of September, Hoechst and Roussel in the UK merged to form a new company, Hoechst Roussel. Roussel Uclaf has a majority stake in the business holding 60%, and Hoechst 40%.

It is anticipated that the new company's consolidated turnover in 1994 should be in excess of L110 million ($172.7 million). Pharmaceutical sales in the UK in 1994 should be around L63 million. The merger moves Hoechst from a ranking in the UK of 51 and Roussel Uclaf of 35 to a consolidated position of 17.

The total number of staff in the UK is 1,100 and there are three main sites: in Denham, where the head office is based; in Swindon where production, research, and pharmaceutical development is located; and in Milton Keynes, which is the joint venture's distribution, drug development and clinical pharmacology center. There is also a distribution site in London which it is anticipated will move to Milton Keynes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight